periconception parental folate, vitamin B12 levels, and risk of birth defects

A prospective cohort study (Shanghai Preconception Cohort) investigated the association between preconception and postconception parental micronutrient levels (RBC folate and vitamin B12) and congenital birth defects (1):

• key finding: preconception parental (maternal and paternal) serum vitamin B12 levels and postconception maternal red blood cell (RBC) folate levels demonstrate significant dose-dependent inverse associations with offspring birth defect rates
• clinical implications: supports the expanding biological understanding of 1-carbon metabolism in human embryogenesis and highlights potential future roles for paternal micronutrient optimization and routine maternal B12 assessment

Key Study Findings

Preconception Parental Vitamin B12

• maternal preconception vitamin B12: strong, inverse dose-response relationship with birth defects
  • predicted birth defect prevalence decreased from 49.6 cases per 1,000 pregnancies in the lowest category (<148 pmol/L) to 16.2 cases per 1,000 pregnancies in the highest category (>=590 pmol/L)
• paternal preconception vitamin B12: demonstrated a similar, though slightly attenuated, protective pattern
  • predicted birth defect prevalence decreased from 55.5 cases per 1,000 pregnancies in the lowest category (<148 pmol/L) to 24.0 cases per 1,000 pregnancies in the highest category (>=590 pmol/L)

Postconception Maternal Folate and B12

• maternal postconception RBC folate:
  • predicted birth defect prevalence was significantly lower at RBC folate levels of 906 to 1,131 nmol/L compared to <453 nmol/L (16.5 vs. 25.7 cases per 1,000 pregnancies)
  • minimal additional risk reduction was observed at concentrations exceeding 1,131 nmol/L, suggesting a potential therapeutic threshold
• maternal postconception vitamin B12:
  • predicted birth defect prevalence remained static across low-to-intermediate categories (148-294 pmol/L) but decreased at higher levels (11.8 vs. 20.4 cases per 1,000 pregnancies at >=590 vs. 148-294 pmol/L)

Supporting Clinical and Guideline Context

1. Established Biological & Epidemiological Literature

• Irish Birth Defects Study Group (Molloy et al., 2009): landmark study demonstrating that deficient or inadequate maternal vitamin B12 status is an independent risk factor for neural tube defects (NTDs) up to 3- to 5-fold, independent of folate status, owing to the interdependent roles of folate and cobalamin in the methionine synthase pathway
  • "Deficient or inadequate maternal vitamin B12 status is associated with a significantly increased risk for neural tube defects. We suggest that women have vitamin B12 levels of >300 ng/L (221 pmol/L) before becoming pregnant."
• NHS / Public Health England Guidelines: acknowledge that low maternal vitamin B12 levels increase the risk of neural tube defects (such as spina bifida and anencephaly) alongside folate deficiency

Current UK Preconception Guidance (NICE NG247)

• routine folic acid supplementation:
  • standard risk: 400 micrograms daily pre-conceptually until 12 weeks of pregnancy
  • high risk (e.g., previous NTD, personal/family history of NTD, maternal anti-epileptic drug therapy, maternal pre-existing diabetes, or malabsorption): 5 mg daily pre-conceptually until 12 weeks of pregnancy
• routine vitamin B12 supplementation:
  • currently not routinely recommended in unselected low-risk pregnancies by NICE or WHO; targeted evaluation is indicated for macrocytic anaemia or suspected malabsorption (e.g., strict vegan diet, previous bariatric surgery, or inflammatory bowel disease)

Reference:

1. Chen H, Chen X, Zhang Y, Li M, Yao Q, Wang D, Zhao Q, et al. Periconception Parental Red Blood Cell Folate, Vitamin B12, and Birth Defects in Offspring: A Prospective Cohort Study. Annals of Internal Medicine. 2026;179(10). DOI: 10.7326/ANNALS-25-05243.
2. Molloy AM, Kirke PN, Troendle JF, Burke H, Sutton M, Brody LC, Scott JM, Mills JL. Maternal vitamin B12 status and risk of neural tube defects in a population with high neural tube defect prevalence and no folic acid fortification. Pediatrics. 2009;123(3):917-923. DOI: 10.1542/peds.2008-1173.
3. National Institute for Health and Care Excellence (NICE). Fetal alcohol spectrum disorder. NICE Guideline [NG247]. Published March 2024.